FDA Proposes Distinct Class I Classification and 510(k) Exemption for Seven Medical Device Accessory Types: Comments Due October 16, 2026

FDA Proposes Distinct Class I Classification and 510(k) Exemption for Seven Medical Device Accessory Types: Comments Due October 16, 2026

On August 17, 2026, the U.S. Food and Drug Administration (FDA) published a notice in the Federal Register (Docket No. FDA-2025-N-6224) proposing to classify seven types of medical device accessories with existing marketing authorization separately in Class I, decoupled from the classification of their parent devices, and to exempt them from 510(k) premarket notification as Class I devices. The accessories involved include non-invasive blood pressure measurement accessories, electrocardiogram cables, extracorporeal membrane oxygenation (ECMO) accessories, auxiliary power supplies for defibrillators, urinary catheter plugs, detachable suction sleeves, and charging accessories for surgical instruments. The document expressly states that it is not a final decision, and the public comment period closes on October 16, 2026.

Source Documents

• U.S. Food and Drug Administration (FDA) — Federal Register: Medical Devices; Classification of Accessories Distinct From Other Devices; Proposed List of Accessories: https://www.federalregister.gov/documents/full_text/html/2026/08/17/2026-16729.html (2026-08-17)
• U.S. Food and Drug Administration (FDA) — CDRH Issues Proposed List of Accessories Suitable for Distinct Classification as Devices: https://www.fda.gov/medical-devices/classify-your-medical-device/cdrh-issues-proposed-list-accessories-suitable-distinct-classification-devices (2026-08-26)
• U.S. Regulations.gov — Docket FDA-2025-N-6224 (Distinct Classification of Accessories in Class I): https://www.regulations.gov/document/FDA-2025-N-6224-0011
• U.S. Food and Drug Administration (FDA) — Medical Device Accessories: Describing Accessories and Classification Pathways (Guidance): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-device-accessories-describing-accessories-and-classification-pathways

News

FDA Proposes to Classify Seven Medical Device Accessory Types Separately as Class I and Exempt Them from 510(k): Comments Due October 16, 2026

Published on October 10, 2026, 13:34. Category: Classification and Technical Guidance.

A compliance change that can easily be overlooked

On August 17, 2026, FDA published a notice in the Federal Register, Docket No. FDA-2025-N-6224, proposing to classify seven types of medical device accessories separately in Class I, decoupling them from the classification of the parent devices to which they originally belonged. The document states that this is not a final decision; FDA will issue a separate final classification action after receiving public comments. The comment deadline is October 16, 2026.

What is the legal basis?

This pathway comes from Section 707 of the FDA Reauthorization Act of 2017 (FDARA), signed on August 18, 2017, corresponding to Section 513(f)(6)(D)(i) of the Federal Food, Drug, and Cosmetic Act. Under that provision, FDA is required to periodically propose a list of accessories that may be classified separately in Class I and to seek public comment. FDA first solicited comments on its website on December 5, 2025 regarding which accessories merit consideration; this notice is the formal proposal developed on that basis.

Which seven accessory types are involved?

The notice's schedule lists seven types of accessories with existing marketing authorization and provides their current classification regulations and product codes:

• 1. Non-invasive blood pressure measurement system accessories (product code DXN, current classification 21 CFR 870.1130): tubing that connects a blood pressure cuff to a non-invasive blood pressure measurement system.
• 2. Electrocardiogram cables (product codes DXY, OSR, current classification 21 CFR 870.3610): used to transmit electrical signals between a pacing device and cardiac pacing leads, or to connect an implantable pacemaker pulse generator system to compatible external equipment, and that do not power the implant or transmit energy to the implant.
• 3. Extracorporeal membrane oxygenation (ECMO) accessories (product codes QJZ, QNR, current classification 21 CFR 870.4100): non-blood-contacting, non-electrical devices used to support, connect, or assemble the ECMO circuit, such as oxygenator mounting brackets or system priming devices; not intended for transport environments.
• 4. Auxiliary power supplies for low-energy direct current defibrillators (AC/DC, product code MPD, current classification 21 CFR 870.5300): accessories that charge the defibrillator battery when the defibrillator is not in use.
• 5. Urinary catheter plugs (product code KNY, current classification 21 CFR 876.5130): sterile plugs used to close the distal end of a urinary catheter to prevent catheter contamination or urine leakage.
• 6. Detachable suction sleeves (product code GEI, current classification 21 CFR 878.4400): detachable plastic components installed at the distal end of a smoke-evacuating monopolar electrosurgical device to direct surgical smoke away from the surgical field; single-use sterile devices.
• 7. Charging accessories for battery-powered surgical instruments (product codes GAG, GDW, current classification 21 CFR 878.4740, 878.4750): accessories that charge the instrument battery.

How does FDA determine eligibility?

FDA explains that whether an accessory is suitable for distinct Class I classification depends on the risk of the accessory for its intended use and the level of regulatory controls necessary to provide reasonable assurance of safety and effectiveness, independent of the parent device classification. In general, three conditions must be met simultaneously: it is not used to support or sustain human life, is not of substantial importance in preventing impairment of human health; it does not present an unreasonable risk of injury or damage; and general controls alone can provide reasonable assurance. Design controls are a key variable—Class I devices generally do not require design controls, but if an accessory must rely on design controls to ensure safety and effectiveness, it is not suitable for this pathway; however, if the accessory is automated by computer software, design control requirements continue to apply. In addition, device-specific accessories designed for a particular parent device according to proprietary dimensions, geometry, or mounting are generally not suitable for distinct classification.

What happens after approval?

For each accessory type in the final list, FDA will write classification regulations into 21 CFR Parts 870, 876, or 878; these accessories will be Class I and exempt from 510(k) premarket notification, subject to applicable exemption limitations. For accessory manufacturers, if a product falls within the list and can demonstrate that general controls are sufficient, the future marketing pathway will be significantly lighter.

How to submit comments

Comments may be submitted via regulations.gov under Docket No. FDA-2025-N-6224 until October 16, 2026, 11:59 p.m. Eastern Time. FDA notes that comments explaining why general controls are sufficient or insufficient, and why design controls are necessary or unnecessary, are more persuasive; if proposing accessories not on the list, product codes or classification regulations should be provided. FDA also noted that earlier comments suggested including reprocessing aids and percutaneous puncture accessories, but these were not separately identified because no product codes and classification regulations were specified.

Sources and scope of application

Sources: This article is based on the FDA's public Federal Register notice (published August 17, 2026, Docket No. FDA-2025-N-6224) and the FDA website explanation page. Original texts: https://www.federalregister.gov/documents/full_text/html/2026/08/17/2026-16729.html and https://www.fda.gov/medical-devices/classify-your-medical-device/cdrh-issues-proposed-list-accessories-suitable-distinct-classification-devices

Verification scope and access date: The above pages were accessed on October 10, 2026, to verify the notice title, docket number, publication date, proposed accessory classification table, comment deadline, and legal basis (FDARA Section 707; Federal Food, Drug, and Cosmetic Act Section 513(f)(6)(D)(i)).

Scope of application: This article is an interpretation of publicly available regulatory information and does not constitute a conclusion or commitment regarding any specific product, company, or registration application; the official original text prevails. Information may change with subsequent official updates; please refer to FDA's final published classification documents.

Information sources

• U.S. Food and Drug Administration (FDA) — Federal Register: Medical Devices; Classification of Accessories Distinct From Other Devices; Proposed List of Accessories, 2026-08-17
• U.S. Food and Drug Administration (FDA) — CDRH Issues Proposed List of Accessories Suitable for Distinct Classification as Devices, 2026-08-26
• U.S. Regulations.gov — Docket FDA-2025-N-6224 (Distinct Classification of Accessories in Class I)
• U.S. Food and Drug Administration (FDA) — Medical Device Accessories: Describing Accessories and Classification Pathways (Guidance)

AIMEILI Regulatory Interpretation

Proposal status and timing. This is a proposed classification action, not a final rule. The comment deadline of October 16, 2026, is therefore a substantive opportunity to influence the final scope. FDA has stated that it will issue final classification action only after considering public comments, so the list of seven accessory types may be narrowed, expanded, or refined.

Eligibility is not automatic. The proposal does not create a blanket exemption for all accessories in these categories. FDA's analysis turns on the accessory's own intended use and risk profile, independent of the parent device. The three conditions—no life-supporting or life-sustaining use, no substantial importance in preventing impairment of human health, no unreasonable risk of injury or damage, and sufficiency of general controls—must be satisfied together. An accessory that narrowly misses any one condition may remain under its current classification and premarket pathway.

Design controls and software are key variables. Class I status generally aligns with general controls, but FDA has expressly flagged design controls as a limiting factor. If safety and effectiveness depend on design controls, the accessory is not a good candidate for this pathway. If the accessory is automated by computer software, design control requirements continue to apply, which may complicate the case for Class I exemption and should be assessed early.

Device-specific accessories are generally excluded. Accessories designed for a particular parent device according to proprietary dimensions, geometry, or mounting are generally not suitable for distinct classification. This distinction is important for manufacturers whose accessory is commercially tied to a single parent device platform.

Postmarket obligations continue. A 510(k) exemption under Class I does not eliminate all regulatory obligations. Unless otherwise exempt, general controls still apply, including establishment registration and device listing, labeling requirements, medical device reporting, and correction and removal reporting. Applicable quality system and recordkeeping requirements should also be confirmed for the specific device type and exemption regulation.

Business Impact

For global medical device manufacturers, distributors, CROs, and regulatory affairs teams, the proposal could materially change U.S. market access planning for certain accessory portfolios. The most immediate impact is on products that fall within the seven proposed categories and can be supported by a general-controls rationale.

• For accessory manufacturers: Products on the final list may avoid the cost, time, and preparation associated with a 510(k) premarket notification. This can accelerate U.S. market entry, simplify lifecycle changes, and improve competitiveness, particularly for low-risk accessory lines that currently rely on the parent device classification.
• For parent device manufacturers: Decoupling accessories from the parent device classification may reduce the regulatory drag on accessory supply and aftermarket parts. However, parent device manufacturers should review whether accessory labeling, instructions for use, and design interfaces still support the parent device's cleared or approved intended use.
• For distributors: The proposal may expand the range of accessory products that can be commercially distributed in the United States without a 510(k), but distributors should verify final classification, exemption limitations, and labeling compliance before relying on Class I exempt status.
• For CROs and regulatory affairs teams: The docket is an opportunity to shape FDA's final list. Comments that provide product codes, classification regulations, and clear general-controls or design-controls reasoning are more likely to be useful to FDA and to clients.

Recommended actions

• Review the accessory portfolio against the seven proposed categories and confirm the applicable product codes and CFR classification regulations.
• Assess each candidate accessory against FDA's conditions: intended use, life-supporting or life-sustaining role, importance in preventing impairment of human health, risk of injury or damage, sufficiency of general controls, and dependence on design controls.
• Determine whether any accessory is device-specific by proprietary dimensions, geometry, or mounting, and therefore likely outside the scope of distinct classification.
• For software-automated accessories, evaluate whether design control requirements continue to apply and whether that affects eligibility.
• Submit comments by October 16, 2026, 11:59 p.m. Eastern Time via regulations.gov under Docket No. FDA-2025-N-6224, especially if proposing additional accessory types or clarifying why general controls are sufficient.
• Monitor FDA's final classification action and update regulatory strategy, technical documentation, labeling, and quality system records accordingly.

Overall view: The proposal is a targeted deregulatory step for selected low-risk accessories. Its practical value depends on final FDA action and on whether a specific accessory can be justified under general controls alone. Companies with accessories in the seven categories should treat the comment period as a strategic window, not merely a compliance formality.